Guardant Health Inc

GH: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
L@sLOCK|<HLOCK|R!&@><v

Guardant Health Earnings: Guidance for 2026 Suggests Strong Momentum for Shield; Fair Value Raised

Guardant reported 33% full-year revenue growth. 2026 guidance includes revenue growth of 27%-30%, Shield volume growth of about 150%, a decline in non-GAAP gross profit margin of about 120 basis points at the midpoint, and significantly improved operating expenses and free cash flow.

Sponsor Center